<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p90" style="overflow: hidden; position: relative; background-color: white; width: 908px; height: 1286px;">

<!-- Begin shared CSS values -->
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<!-- End shared CSS values -->


<!-- Begin inline CSS -->
<style type="text/css" >

#t1_90{left:130px;bottom:1195px;letter-spacing:0.22px;}
#t2_90{left:804px;bottom:1195px;letter-spacing:0.13px;}
#t3_90{left:238px;bottom:1115px;letter-spacing:-0.01px;}
#t4_90{left:238px;bottom:1096px;letter-spacing:-0.01px;}
#t5_90{left:238px;bottom:1076px;letter-spacing:-0.01px;}
#t6_90{left:238px;bottom:1057px;letter-spacing:-0.01px;}
#t7_90{left:238px;bottom:1038px;letter-spacing:-0.01px;}
#t8_90{left:238px;bottom:1018px;letter-spacing:-0.01px;}
#t9_90{left:238px;bottom:999px;letter-spacing:-0.01px;}
#ta_90{left:238px;bottom:979px;letter-spacing:-0.01px;}
#tb_90{left:238px;bottom:960px;letter-spacing:-0.01px;}
#tc_90{left:238px;bottom:940px;letter-spacing:-0.01px;}
#td_90{left:238px;bottom:921px;letter-spacing:-0.01px;}
#te_90{left:238px;bottom:901px;letter-spacing:-0.01px;}
#tf_90{left:238px;bottom:882px;letter-spacing:-0.01px;}
#tg_90{left:238px;bottom:863px;letter-spacing:-0.01px;}
#th_90{left:238px;bottom:770px;letter-spacing:-0.01px;}
#ti_90{left:238px;bottom:750px;letter-spacing:-0.01px;}
#tj_90{left:238px;bottom:731px;letter-spacing:-0.01px;}
#tk_90{left:238px;bottom:711px;letter-spacing:-0.01px;}
#tl_90{left:238px;bottom:692px;letter-spacing:-0.01px;}
#tm_90{left:238px;bottom:638px;letter-spacing:-0.01px;}
#tn_90{left:238px;bottom:618px;letter-spacing:-0.01px;}
#to_90{left:238px;bottom:599px;letter-spacing:-0.01px;}
#tp_90{left:238px;bottom:579px;letter-spacing:-0.01px;}
#tq_90{left:238px;bottom:560px;letter-spacing:-0.01px;}
#tr_90{left:238px;bottom:541px;letter-spacing:-0.01px;}
#ts_90{left:238px;bottom:521px;letter-spacing:-0.01px;}
#tt_90{left:238px;bottom:502px;letter-spacing:-0.01px;}
#tu_90{left:238px;bottom:482px;letter-spacing:-0.01px;}
#tv_90{left:238px;bottom:463px;letter-spacing:-0.01px;}
#tw_90{left:238px;bottom:443px;letter-spacing:-0.01px;}
#tx_90{left:238px;bottom:350px;letter-spacing:-0.01px;}
#ty_90{left:238px;bottom:331px;letter-spacing:-0.01px;}
#tz_90{left:238px;bottom:311px;letter-spacing:-0.01px;}
#t10_90{left:238px;bottom:292px;letter-spacing:-0.01px;}
#t11_90{left:238px;bottom:273px;letter-spacing:-0.01px;}
#t12_90{left:238px;bottom:253px;letter-spacing:-0.01px;}
#t13_90{left:238px;bottom:234px;letter-spacing:-0.01px;}
#t14_90{left:238px;bottom:214px;letter-spacing:-0.01px;}
#t15_90{left:238px;bottom:195px;letter-spacing:-0.01px;}
#t16_90{left:238px;bottom:175px;letter-spacing:-0.01px;}
#t17_90{left:202px;bottom:69px;letter-spacing:0.23px;}

.s0_90{font-size:11px;font-family:NotoSans-Regular_7j-;color:#000;}
.s1_90{font-size:12px;font-family:NotoSans-Regular_7j-;color:#000;}
.s2_90{font-size:13px;font-family:NotoSans-Regular_7j-;color:#000;}
</style>
<!-- End inline CSS -->

<!-- Begin embedded font definitions -->
<style id="fonts90" type="text/css" >

@font-face {
	font-family: NotoSans-Regular_7j-;
	src: url("fonts/NotoSans-Regular_7j-.woff") format("woff");
}

</style>
<!-- End embedded font definitions -->

<!-- Begin page background -->
<div id="pg90Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg90" style="-webkit-user-select: none;"><object width="908" height="1286" data="90/90.svg" type="image/svg+xml" id="pdf90" style="width:908px; height:1286px; -moz-transform:scale(1); z-index: 0;"></object></div>
<!-- End page background -->


<!-- Begin text definitions (Positioned/styled in CSS) -->
<div class="text-container"><span id="t1_90" class="t s0_90">7.7. Residual tumor, recurrence and recurrent metastasis </span><span id="t2_90" class="t s1_90">90 </span>
<span id="t3_90" class="t s2_90">Over 70% of patients with a residue or recurrence after unsuccessful radiochemotherapy have </span>
<span id="t4_90" class="t s2_90">advanced tumors and almost half of the patients have transglottic T3 or T4 tumors [296]. In </span>
<span id="t5_90" class="t s2_90">this situation, imaging and endoscopy often lead to an incorrect assessment of the tumor size </span>
<span id="t6_90" class="t s2_90">in the sense of "understaging", since the assessment of the tissue is considerably more difficult </span>
<span id="t7_90" class="t s2_90">due to post-radiogenic edema and scarring. Pretherapeutic clinical examination and imaging </span>
<span id="t8_90" class="t s2_90">only have an accuracy of about 50% in the case of recurrence, with up to 90% of recurring </span>
<span id="t9_90" class="t s2_90">tumors being estimated as too small [256]. In addition, recurring tumors often show </span>
<span id="ta_90" class="t s2_90">multicentric tumor foci that may exceed the limits of the primary tumor size. In a retrospective </span>
<span id="tb_90" class="t s2_90">analysis of 173 patients with tumor recurrences after radiotherapy of early glottic carcinomas, </span>
<span id="tc_90" class="t s2_90">a comparison with the initial T category of the primary tumor showed that 61% of the </span>
<span id="td_90" class="t s2_90">recurrences had a higher rT category, 31% of the recurrences had the same rT category as the </span>
<span id="te_90" class="t s2_90">primary tumor, and only 8% had a lower rT category in the sense of down-staging [297]. For </span>
<span id="tf_90" class="t s2_90">this reason, in the recurrence situation after primary radio(chemo)therapy, resection at least in </span>
<span id="tg_90" class="t s2_90">the original tumor borders is usually advisable. </span>
<span id="th_90" class="t s2_90">Successful management in the recurrence situation depends on strict selection criteria. In </span>
<span id="ti_90" class="t s2_90">particular, when planning transoral surgery and open partial laryngeal resections, a careful </span>
<span id="tj_90" class="t s2_90">assessment of the location, growth and extent of the recurrence tumor should be carried </span>
<span id="tk_90" class="t s2_90">out. An R0 resection is also of considerable prognostic value in the recurrence situation and </span>
<span id="tl_90" class="t s2_90">should be the primary goal of the surgical procedure [298]. </span>
<span id="tm_90" class="t s2_90">In the available studies, disease-free survival in an average observation period of 38 months </span>
<span id="tn_90" class="t s2_90">after transoral laser therapy for recurrences after primary radio(chemo)therapy is between 43% </span>
<span id="to_90" class="t s2_90">and 90% [299]. Data on local control after a single transoral laser therapy in the recurrence </span>
<span id="tp_90" class="t s2_90">situation vary in the literature between 38% and 85% [6, 300]. Repeated laser surgical resections </span>
<span id="tq_90" class="t s2_90">in the case of recurrence after previous radiotherapy are possible and can improve local control, </span>
<span id="tr_90" class="t s2_90">as shown by Steiner et al., who were able to increase local control from an initial 38% to 71% </span>
<span id="ts_90" class="t s2_90">through repeated laser surgical resection. Other authors report local control rates of 50% to </span>
<span id="tt_90" class="t s2_90">82% after multiple laser resections in the case of recurrence after primary radio(chemo)therapy </span>
<span id="tu_90" class="t s2_90">[301]. On the other hand, Roedel et al. In case of recurrence after transoral laser surgery, early </span>
<span id="tv_90" class="t s2_90">laryngectomy should be considered, as local control after repeated transoral surgery is </span>
<span id="tw_90" class="t s2_90">unfavorable [302]. </span>
<span id="tx_90" class="t s2_90">There is a meta-analysis of retrospective case series on transoral laser surgery after primary </span>
<span id="ty_90" class="t s2_90">radio(chemo)therapy from 2014 [303]. Only one of the included studies was a case series with </span>
<span id="tz_90" class="t s2_90">exclusively prospective inclusion of cases. The pooled estimate of the 2-year overall survival </span>
<span id="t10_90" class="t s2_90">after transoral laser therapy in the recurrence situation was 74.8%. Larynx preservation was </span>
<span id="t11_90" class="t s2_90">achieved in 72.3% of patients. The local control of the total of 286 patients was 56.9% after one </span>
<span id="t12_90" class="t s2_90">laser surgery procedure, 63.8% after multiple laser surgery procedures, and 88.2% after salvage </span>
<span id="t13_90" class="t s2_90">laryngectomy. Based on the available limited evidence, it can be concluded that transoral laser </span>
<span id="t14_90" class="t s2_90">surgery in the recurrence situation after prior radiation should only be offered in carefully </span>
<span id="t15_90" class="t s2_90">selected cases. This should be done in centers that have a high level of expertise in transoral </span>
<span id="t16_90" class="t s2_90">laser surgery and, if possible, also offer open </span>
<span id="t17_90" class="t s0_90">Â© Oncology Guideline Program | S3 Guideline Laryngeal Carcinoma | Long Version 1.0 | January 2019 </span></div>
<!-- End text definitions -->


</div>
</body>
</html>
